Product Center
  • Trabectome

  • MIGS new technique
    The first line Glaucoma surgery in US and EU

    Product Characteristics:
    1. Micro Invasion:1.8mm cornea incision、no invasion to conjunctiva and sclera
    2. Longer treatment affection:IOP decreasing 40% post-op
       Medications decreasing 25%~43% post-op
       Stable IOP and medications after 90 months follow-up
    3. Safty:Lowest side-effect and complication post-op
       No implant and related risk
       No filtering bleb, and no affected other filtering surgery

National after-sales service hotline



Gaush Medical Wechat Public Account